Photos: 

Some evaluation reports are public and can be downloaded from this website, while others are restricted to MSF users and can only be accessed via Tukul. This limitation is mainly due to the sensitive nature of the operational contexts and the resulting content. However, there are internal discussions about making all evaluation reports publicly searchable. If you are an MSF association member, reports are made available on various associate platforms such as www.insideOCB.com.

Country/Region

In 2015, MSF operations and medical directors recognised antibiotic resistance (ABR) as a priority and called for the elaboration of an intersectional roadmap to tackle ABR in MSF projects. The MSF ABR Task Force was consolidated in 2017 with joint medical and operational governance.

These case study reports were produced at the request of MSF-OCBA, under the management of the Vienna Evaluation Unit. They were prepared independently by the respective authors.
09/09/2019

This document describes the project Lessons identified at the end of the market entry planning phase for MSF in Finland. It summarises the successes and challenges encountered during the project, lists the learning themes arising from these successes and challenges, and includes a set of lessons derived from an analysis of these learning points. The Annex contains a proposed (brief) framework with criteria and pre-requisites for a successful Market Entry Plan in MSF based on this experience. NOTE: This is not an evaluation and therefore there is no ambition for independent judgement.

This Retrospect was facilitated by the Stockholm Evaluation Unit on behalf of the Project Team. The report has been prepared by Timothy McCann.
30/10/2017

The Ebola Workshop in Dakar, held over 3 days in June 2015, brought together experienced Ebola field people and HQ staff from diverse specialties and all MSF sections to reflect on lessons learned so far and make recommendations in the areas of outreach response, patient care, human resources and strategy. Participants placed a high value on intersectional approaches within MSF, and on strong engagement with key external organizations in preparing flexible, adapted, more effective responses to future outbreaks of Ebola or other mass epidemics. 

By Patricia Kahn, with input from Sebastian Stein. Based on summaries by Amanda Tiffany, Roberta Petrucci, Ruth Kauffman and Sebastian Stein.
01/07/2015

This report summarises the key lessons learned from MSF's cholera interventions in Zambia 2004, 2006, 2008, 2010 (OCBA), Guinea Bissau 2005-2008 (OCBA), Juba 2006 (OCBA), Haiti 2010-2011 (OCBA), Angola 2006 (OCB, OCA, OCBA), Zimbabwe 2009 (OCB, OCA, OCBA)

M Iscla
09/05/2012

Since civil unrest and violence erupted in countries across Northern Africa and the Middle East (referred as NAME in the document) teams from the five MSF OCs (Operational Centres) have been assisting the populations. OCB has mainly been active in Egypt, Bahrain, Libya and Italy (Lampedusa with the influx of migrants from the Northern African regions). Activities and challenges have varied from one context to another. The overall aim of the mapping/compilation is to describe all of OCB’s activities from January to August 2011, in relation to the unrests.

David Crémoux
01/09/2011

The evaluation analysed MSF intervention strategies of the TB project in the Penal sector of Kyrgyzstan by reviewing relevance, effectiveness and continuity. It assessed current challenges and shortcomings of the intervention in order to recommend new techniques and approaches for the year 2011 and beyond.

Gill Bradbury, Walli Wernhart, and Dr. A.Jamil Faqirzai
08/10/2010

The Bosnia programme was one of the largest programmes MSF has implemented so far, and it was the first major operation MSF executed in an European environment. There was a widely shared view that the programme had gone “out of control”. As a result, many within MSF considered drug distribution in general as being beyond the scope of MSF. The dominance of drug distribution in the programme was perceived to be in contradiction with the medical identity of MSF.

Van de Putte, B. and Maslesa, L.
01/04/1998